AEterna Zentaris Affirms Focus On Targeted Oncology During 2016 J.P. Morgan Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Aeterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the “Company”) today affirmed its focus on targeted oncologic therapies during the 2016 J.P. Morgan Healthcare Conference, where interest in such therapies remains very strong.
Dr. Richard Sachse, the Company’s Chief Scientific Officer, characterized the interest expressed by oncology companies attending the conference as “intense”, stating as follows: “Immuno-oncology/targeted oncology has been one of the key areas of innovation over the last few years. That is certainly still true today as evidenced by the number of companies presenting developments in this area at J.P. Morgan. We have been at the vanguard of this innovation with our portfolio of targeted oncology compounds, which includes Zoptrex™ (zoptarelin doxorubicin) and our Disorazol Z cytotoxic conjugate, AEZS-138.”
Dr. Richard Sachse, the Company’s Chief Scientific Officer, characterized the interest expressed by oncology companies attending the conference as “intense”, stating as follows: “Immuno-oncology/targeted oncology has been one of the key areas of innovation over the last few years. That is certainly still true today as evidenced by the number of companies presenting developments in this area at J.P. Morgan. We have been at the vanguard of this innovation with our portfolio of targeted oncology compounds, which includes Zoptrex™ (zoptarelin doxorubicin) and our Disorazol Z cytotoxic conjugate, AEZS-138.”